Development of a vaccine against human cytomegalovirus: advances, barriers, and implications for the clinical practice

S Scarpini, F Morigi, L Betti, A Dondi, C Biagi, M Lanari - Vaccines, 2021 - mdpi.com
Human cytomegalovirus (hCMV) is one of the most common causes of congenital infection
in the post-rubella era, representing a major public health concern. Although most cases are …

The CD4+ T cell response to human cytomegalovirus in healthy and immunocompromised people

EY Lim, SE Jackson, MR Wills - Frontiers in cellular and infection …, 2020 - frontiersin.org
While CD8+ T cells specific for human cytomegalovirus (HCMV) have been extensively
studied in both healthy HCMV seropositive carriers and patients undergoing …

Cytomegalovirus in solid organ transplant recipients—Guidelines of the American Society of Transplantation Infectious Diseases Community of Practice

RR Razonable, A Humar - Clinical transplantation, 2019 - Wiley Online Library
Cytomegalovirus (CMV) is one of the most common opportunistic infections that affect the
outcome of solid organ transplantation. This updated guideline from the American Society of …

Ulcerative, vesicular, and bullous lesions

SB Woo, JF Setterfield, MS Greenberg - Burket's oral medicine, 2021 - books.google.com
Many ulcerative or vesiculobullous disease of the mouth have a similar clinical appearance.
The oral mucosa is thin, and even slight trauma leads to rupture of vesicles and bullae …

[HTML][HTML] In vitro comparison of currently available and investigational antiviral agents against pathogenic human double-stranded DNA viruses: A systematic literature …

RF Chemaly, JA Hill, S Voigt, KS Peggs - Antiviral Research, 2019 - Elsevier
Background Double-stranded (ds) DNA virus infections often occur concomitantly in
immunocompromised patients. We performed a systematic search of published in vitro …

Cytomegalovirus therapy: role of letermovir in prophylaxis and treatment in transplant recipients

JL Saullo, RA Miller - Annual Review of Medicine, 2023 - annualreviews.org
Cytomegalovirus (CMV) is a common viral pathogen in the transplant population and is
associated with significant morbidity and mortality. CMV prevention is paramount; however …

[HTML][HTML] Cytomegalovirus management in solid organ transplant recipients: a pre-COVID-19 survey from the working group of the European Society for organ …

PA Grossi, N Kamar, F Saliba… - Transplant …, 2022 - frontierspartnerships.org
Infections are leading causes of morbidity/mortality following solid organ transplantation
(SOT) and cytomegalovirus (CMV) is among the most frequent pathogens, causing a …

New trends in the management of cytomegalovirus infection after allogeneic hematopoietic cell transplantation: a survey of the Infectious Diseases Working Pary of …

S Cesaro, P Ljungman, G Tridello, M Mikulska… - Bone Marrow …, 2023 - nature.com
The management of cytomegalovirus (CMV) infection was assessed with a survey
performed in 2020 by the Infectious Diseases Working Party of European Society for Blood …

Assessment and prevention of cytomegalovirus infection in allogeneic hematopoietic stem cell transplant and in solid organ transplant: a multidisciplinary consensus …

C Girmenia, T Lazzarotto, F Bonifazi… - Clinical …, 2019 - Wiley Online Library
Cytomegalovirus (CMV) remains a major cause of morbidity and mortality in allogeneic
hematopoietic stem cell transplantation (allo‐HSCT) and solid organ transplantation (SOT) …

Adoptive therapy with cytomegalovirus‐specific T cells for cytomegalovirus infection after haploidentical stem cell transplantation and factors affecting efficacy

XY Pei, XY Zhao, XF Liu, XD Mo, M Lv… - American Journal of …, 2022 - Wiley Online Library
Adoptive therapy with cytomegalovirus (CMV)‐specific cytotoxic T lymphocytes (CMV‐CTLs)
has emerged as an effective method for CMV infection. However, the efficacy reportedly …